<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1285">
  <stage>Registered</stage>
  <submitdate>5/09/2006</submitdate>
  <approvaldate>5/09/2006</approvaldate>
  <nctid>NCT00372801</nctid>
  <trial_identification>
    <studytitle>Effectiveness Of Single Doses Of Ibuprofen In Patients With Osteoarthritis Of The Knee</studytitle>
    <scientifictitle>A Double-Blind, Randomised, Placebo-Controlled, Cross-Over Pilot Study to Investigate the Efficacy of Ibuprofen in Patients With Osteoarthritis of the Knee Following Administration of a Single Dose</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>COX103843</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Osteoarthritis</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoarthritis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Ibuprofen

Treatment: drugs: Ibuprofen


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Pain intensity recorded over 0-8 hours using question 1 of the WOMAC (Western Ontario and McMaster University Osteoarthritis Index)pain subscale (visual analog scale).</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Responder rate Patient impression of change - 8 &amp; 24 hrs post dose Time to use of rescue medication (paracetamol)</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion criteria:

          -  Subjects diagnosed with primary Osteoarthritis of the knee.

          -  Have at least 3 months in symptom duration prior to screening visit.

          -  Regular user of a prescribed non-steroidal anti-inflammatory drug (NSAID) or selective
             cyclo-oxygenase II (COX2) inhibitor for management of knee pain.

          -  Pain walking on flat surface within specific interval prior to study start.</inclusivecriteria>
    <inclusiveminage />
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion criteria:

          -  History of hypersensitivity to NSAIDS.

          -  Allergy to Ibuprofen.

          -  Use of assistive devices other than a cane or knee brace.

          -  History of specified diseases/illnesses.

          -  Abnormal blood tests pre-study.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2005</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>GSK Investigational Site - Randwick, Sydney</hospital>
    <postcode>2031 - Randwick, Sydney</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>GlaxoSmithKline</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>To demonstrate that new drugs work, many complex multidose studies are often required. The
      intent of this study is to use Ibuprofen as an example of a marketed pain relief drug to
      validate a simpler single dose model for future assessment of new pain drugs.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00372801</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>GSK Clinical Trials</name>
      <address>GlaxoSmithKline</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>